Slingshot members are tracking this event:

PALOMA-2 Phase 3 Study Published In The New England Journal Of Medicine Demonstrates Clinical Benefit Of Pfizer’s IBRANCE (palbociclib) In First-Line ER+, HER2- Metastatic Breast Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
PFE Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 16, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Ibrance, Palbociclib, Her2- Metastatic Breast Cancer, Paloma-2